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ABSTRACT 28	
 29	
This pilot study compared placental growth factor (PlGf) levels in populations with 30	
high versus low risk for cardiac disease. Previous experiments from our laboratory 31	
(Sundaresan et al. 2005; 2009) revealed that the angiogenic factor PlGf was up-32	
regulated in modeled microgravity conditions in human lymphocytes leading to 33	
possible atherogenesis and pathogenesis in microgravity. Since the findings came 34	
from simulated microgravity experiments, there is a strong link to its usefulness in 35	
the microgravity field as a biomarker. The relevance is enhanced because in life on 36	
earth, it is a cardiovascular inflammatory marker. Studies on the levels of PIGF 37	
would help to give a hint about the risk of heart failures in astronauts.		 38	
 39	
The investigations here were only to confirm that in a cardiovascular stressed 40	
population such as CAD and ACS patients, PlGf could be overexpressed.  41	
We desired to evaluate this marker in stressed cardiac disease patients. PlGf is a 42	
marker of inflammation and a predictor of short-term and long-term adverse 43	
outcome in acute coronary syndrome (ACS). In addition, elevated PlGf levels may 44	
be associated with increased risk for coronary heart disease. PlGf levels were 45	
determined in thirty-one patients undergoing cardiac catheterization for reasons 46	
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other than ACS and in thirty-three low-risk asymptomatic subjects. Additional data 47	
on traditional cardiac risk factors for both populations were also compiled and 48	
compared.  We found that PlGf levels were significantly higher in the high-risk 49	
than low-risk population and correlated inversely with HDL-cholesterol but 50	
directly with the triglyceride levels. With further validation, PlGf may prove a 51	
useful addition to the armamentarium of noninvasive biomarkers for cardiac 52	
disease including a new area of stressful physiological conditions such as 53	
microgravity.  54	
 55	
Key words:  PlGf; catheterization; coronary artery disease, ACS 56	
INTRODUCTION 57	
 58	
Previous experiments from our laboratory (Sundaresan et al. 2005; 2009) revealed 59	
that the angiogenic factor PlGf was up-regulated in modeled microgravity conditions 60	
in human lymphocytes. Prior to this both in true space flight and modeled 61	
microgravity culture conditions in our laboratory and in others, immune suppression 62	
was observed via depressed lymphocyte activation and locomotion (Sundaresan et 63	
al. 2004). Delineation of the mechanisms via signal transduction revealed mishaps 64	
in trans-membrane signaling at or above the level of Protein Kinase C (PKC). 65	
This led to further characterization of the adaptational versus functional alterations 66	
in the human lymphocytes in response to microgravity. The next step in the PlGf 67	
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experiments was to corroborate the gene array findings with real time PCR. RT 68	
PCR was carried out for PlGf to confirm the gene array results (Sundaresan et 69	
al. 2005; 2009). Peripheral blood lymphocyte cells from normal human donors 70	
were isolated by the Ficoll-Paque method. Half the cell population obtained was 71	
split into two for 1g and modeled microgravity culture (Sundaresan et al. 2002, 72	
2004). Cells were harvested at 72 hours and pelleted for RNA extraction and 73	
Protein determination by standard protocols. RT- PCR was performed with hPlGf 74	
and hGAPdH primers by standard procedures starting with 300 ng of RNA per 75	
sample in triplicate.  76	
From the RT- PCR conducted on peripheral blood from four normal donors all of 77	
whom were male, previous work (Sundaresan et al. 2005; 2009) showing up-78	
regulation of PlGf was confirmed. The data from our laboratory and from other 79	
laboratories (Heeschen et al. 2004; Sundaresan et al. 2004) suggests that 80	
microgravity can lead to increased inflammatory responses. The implication of this 81	
data cannot be ignored especially as missions to the Moon and Mars will soon be 82	
reality.  83	
Anecdotal evidence from astronaut samples (serum or urine, baseline, pre and post 84	
flight) will be proposed soon. A holistic approach from cell to whole body 85	
physiology especially looking at important physiological effectors is warranted. 86	
Hence we hypothesized that PlGf would be elevated, compared to in healthy 87	
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asymptomatic subjects, in stable patients who were nonetheless still at high risk for 88	
cardiac disease. 89	
 90	
Placental induced growth factor (PlGf), first detected in the placenta, is a member 91	
of the vascular endothelial growth factor family (VEGF). PlGf is strongly up-92	
regulated in early and advanced atherosclerotic lesions and acts as a primary 93	
inflammatory instigator of atherosclerotic plaque instability (Lenderink et al 2006). 94	
Results from the CAPTURE trial suggest that PlGf is an independent biomarker of 95	
short-term adverse outcome in patients with ACS (Lenderink et al 2006).  96	
There are also data suggesting that elevated PlGf is associated with adverse long-97	
term outcome post ACS (Lenderink et al 2006). A nested-case control 98	
investigation of the Nurses Health Study, a 14 year follow-up of 32,826 women 99	
who were healthy at baseline, showed elevated PlGf as a predictor for coronary 100	
artery disease. Previous investigations revealed a more than five-fold increase 101	
(p<0.001) in angiogenesis inducers, including PlGf, in normal human lymphocytes 102	
in a physiological stress environment in modeled microgravity, a space cell culture 103	
analog. Up-regulation of PlGf suggests de-regulation of cardiovascular signaling 104	
pathways (Cassidy et al 2009). These observations raise the question of PlGf 105	
participation in the stresses of cardiovascular disease in different altered 106	
physiological environments such as spaceflight. Genetic response suites in human 107	
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lymphocytes in response to microgravity and high altitude stress enable 108	
identification and further study in order to augment human physiological 109	
adaptation to novel environments.   110	
The DNA micro array has the potential to identify novel genes involved in 111	
mediating adaptation to environments associated with stress.  The study of such 112	
genes essential to adaptation is valuable for identifying potential new targets for 113	
therapeutic countermeasures, or as predictive biomarkers of novel response. PlGf 114	
is named for the organ in which it was first detected and is a newly described 115	
molecular marker of inflammation.  116	 It	is	a	major	component	in	the	inflammatory	process	and	a	proven	marker	for	117	 event	risk	in	the	context	of	acute	coronary	syndrome	(ACS),	stroke	and	other	118	 cardiovascular	conditions	(Heeschen	et	al	2004).	It	is	now	considered	a	more	119	 specific	biomarker	than	C-reactive	protein	for	predicting	stroke	and	120	 myocardial	infarction,	and	is	up-regulated	significantly	in	early	onset	and	121	 progressive	stages	of	cardiovascular	dysfunction.		It	may	be	an	early	indicator	122	 of	ACS	in	individuals	who	suffer	chest	pain	serious	enough	to	bring	them	to	123	 emergency	rooms,	with	elevated	levels	of	PlGf	also	predicting	increased	risk	of	124	 ACS-related	mortality	(Heeschen	et	al	2004).		Previous	experiments	from	our	125	 laboratory	(Sundaresan	et	al.	2005;	2009)	revealed	that	the	angiogenic	factor	126	 PlGf	was	up-regulated	in	modeled	microgravity	conditions	in	human	127	
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lymphocytes.	We	thus	hypothesized	that	PlGf	levels	would	also	be	elevated,	128	 compared	to	in	healthy	asymptomatic	subjects,	in	stable	patients	who	were	129	 nonetheless	still	at	high	risk	for	cardiac	disease. Since the findings came from 130	
simulated microgravity experiments, there is a strong link to its usefulness in the 131	
microgravity field as a biomarker. The relevance is enhanced because in life on 132	
earth, it is a cardiovascular inflammatory marker. Studies on the levels of PIGF 133	
would help to give a hint about the risk of heart failures in astronauts.		 134	
 135	
The investigations here were only to confirm that in a cardiovascular stressed 136	
population such as CAD and ACS patients, PlGf could be overexpressed.  137	
 138	
 139	
 140	
 141	
 142	
 143	
 144	
 145	
METHODS 146	
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After obtaining institutional review board approvals for the pilot study and written 147	
informed consent from each participant, blood samples were taken just before 148	
catheterization from 31 patients undergoing cardiac catheterization and from 33 149	
healthy controls. PlGf levels were measured in all blood samples by an 150	
immunoassay (R and D, Minnesota, DPG000).  151	
Data related to traditional cardiac risk factors were also collected (Table 1), 152	
including total cholesterol, LDL, HDL and triglyceride levels (Table 2). Results of 153	
cardiac catheterization and of other studies such as EKG, echocardiogram and 154	
cardiac stress testing were also compiled.  155	
RESULTS 156	
PlGf in the asymptomatic subjects studied thus far (N=33) is just 16.5 ± 6.6 ng/L 157	
(mean ± SD) versus 91.2 ± 51.6 ng/L (p<0.001) in a subgroup of patients with 158	
known coronary artery disease (N=30).  These groups were all patients   who went 159	
in for catheterization and most had proven CAD. In the latter group, the mean 160	
value is increased well beyond the clinical threshold level (>27ng/L) (Table 2, 161	
Figure 1). Case history details were also collected to analyze correlations between 162	
PlGf and cardiovascular risk markers. There was an inverse correlation between 163	
PlGf and HDL cholesterol (Figure 2) and a direct correlation between PlGf and 164	
triglycerides (Figure 3).   165	
DISCUSSION 166	
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In this pilot study, patients undergoing cardiac catheterization for any reason had 167	
PlGf levels significantly higher than healthy control subjects.  And in turn our 168	
small group of healthy controls had PlGf levels similar to those of the healthy 169	
women included in the 32,826 Nurses Health Study (PlGf = 16.1) (Cassidy et al 170	
2009). Our patients undergoing catheterization were older, more predominantly 171	
male and had more cardiac risk factors than the healthy controls.  While none of 172	
the catheterized patients was undergoing catheterization for evaluation of possible 173	
ACS, five (16%) had a personal history of a prior myocardial infarction, ten more 174	
(32%) had significant coronary artery disease (CAD) discovered during the cardiac 175	
catheterization that required intervention, and a total of 24 (77%) had some form of 176	
known previous or current CAD.  There is no question therefore that the 177	
catheterized patient population had a high burden of cardiac disease, particularly 178	
CAD. 179	
PlGf was inversely proportional to HDL-cholesterol level and directly proportional 180	
to triglyceride level.  This may signify a true correlation or simply the fact that all 181	
three of these biomarkers may be construed as risk markers for CAD.  Being a 182	
pilot study, our study is insufficiently powered to explore any but the most 183	
superficial of relationships. However, it is worthwhile to note that other studies 184	
have shown similar correlations in larger populations (Cassidy et al 2009).   185	
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Lastly, LDL-cholesterol did not appear to be different amongst the two groups 186	
(Figure 4). This may be due to a number of reasons including power, but also the 187	
fact that a larger number of patients in the catheterization group were on lipid 188	
lowering medications that primarily act on LDL.  189	
In patients with ACS, the presence of thrombogenic contents in the circulation may 190	
be responsible for the plaque rupture (Cassidy et al 2009). Specifically, most cases 191	
of ACS probably result from platelet activation and thrombus formation (Cassidy 192	
et al 2009).  In previous studies, levels of PlGf have not correlated with levels of 193	
troponin (Cassidy et al 2009), the latter being principally a marker of cardiac 194	
muscle injury. These results suggest that PlGF elevations are likely driven by a 195	
different mechanism of cardiovascular injury, i.e., inflammation and 196	
atherosclerosis. Overall, the present findings suggest that the concentration of 197	
PlGF, a more specific marker of vascular inflammation, is likely to be significantly 198	
increased in populations with high cardiac disease burdens.  199	
Besides the overall small number of participants, this pilot study was also limited 200	
by the heterogeneity of cardiac disease types in the catheterized population (i.e., 201	
not just CAD) and by the significant age, gender and risk factor differences 202	
between the catheterized and healthy control groups (Tables 1 and 2). Nevertheless 203	
there seems to be little question that patient groups with a high burden of coronary 204	
heart disease have higher levels of PlGf.   205	
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Moreover our results are consistent with those of previous studies (Cassidy et al 206	
2009). Hence in conclusion, the elevated levels of PlGf at the protein and RNA 207	
levels both in in vitro and in vivo models of analog microgravity suggest that 208	
further studies of PlGf in astronauts will be beneficial to the space program. This 209	
pilot study was to ascertain if PlGf was elevated in high risk cardiac disease 210	
populations compared to healthy controls to pave the way for future studies in 211	
astronauts and in aviation medicine. 212	
 213	
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FIGURE LEGENDS 260	
 261	
 262	
Figure 1.  PlGf levels in control subjects (N=33; 16.5 ± 6.6 ng/L, mean ± SD) 263	
versus in a (subgroup of patients with known coronary artery disease (N=30; 91.2 264	
± 51.6 ng/L (p<0.001)).  265	
 266	
Figure 2.  Inverse correlation between levels of PlGF and high density lipoprotein 267	
(HDL)  268	
 269	
Figure 3.  Direct correlation between levels of PlGF and triglycerides in the entire 270	
group of catheterized patients.  271	
  272	
Figure 4.  Lack of correlation between levels of PlGf and low density lipoprotein 273	
(LDL) in the entire group of catheterized patients  274	
 275	
 276	
 277	
 278	
 279	
 280	
 281	
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Table 1.  Demographics 282	
  
Catheterized 
Patients 
Controls 
Age 64.4 49.5 
Male 97% 67% 
Coronary Artery Disease 77% none 
Traditional Cardiac Risk 
Factors and related 3.97 1.5 
    Hypertension 87% 26% 
    Hyperlipidemia 77% 37% 
    Lipid Lowering Agent 67% 17% 
 
    Hyperglycemia or Diabetes 48% 22% 
    Tobacco Use 48% none 
 283	
 284	
 285	
 286	
 287	
 288	
 289	
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Table 2.  Results 290	
PlGf and Fasting Lipid Panel 
  
Catheterized 
Patients Controls  
p 
PlGf 91.2  14  p<0.001 
Cholesterol 162.6  173.9  p<0.1 
LDL 94  104.1  P<0.2 
HDL 36.8  53.9  p<0.001 
Triglycerides 149.4  100.9  p<0.001 
 291	
  292	
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 293	
 294	
Figure 1.  PlGf levels in catheterized patients versus controls  295	
  296	
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 316	
Figure 2: Inverse correlation between levels of PlGF and high density lipoprotein 317	
(HDL) in catheterized patients.  318	
  319	
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Figure 3: Direct correlation between levels of PlGF and triglycerides in 342	
catheterized patients.    343	
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 345	
 346	
 347	
 348	
 349	
Figure 4: Lack of correlation between levels of PlGf and low density lipoprotein 350	
(LDL) in catheterized patients.  351	
 352	
 353	
